Merck’s Anti-PD1 Therapy Receives Second FDA Approval for Esophageal Carcinoma
On March 23rd, pharma giant Merck announced their anti-PD1 therapy, Keytruda, in combination with platinum- and fluoropyrimidine-based chemotherapy received FDA approval for the treatment of advanced or metastatic esophageal or …
Read More